ArticlePharmaceutics2025
Optimizing Dose Conversion from IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling Study.
Zeyar Mohammed Ali, Beatriz Fernández-Alarcón, Pere Fontova, Anna Vidal-Alabró, Raul Rigo-Bonnin, Edoardo Melilli, Nuria Montero, Anna Manonelles, Ana Coloma, Alexandre Favà and 4 more
Abstract read
In one paragraphArticle in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Zeyar Mohammed AliNephrology Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.
Beatriz Fernández-AlarcónNephrology Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.
Pere FontovaNephrology Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.ORCID 0000-0002-1352-3084 Anna Vidal-AlabróNephrology Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.
Raul Rigo-BonninBiochemistry Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.ORCID 0000-0001-5511-074X Edoardo MelilliNephrology Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.ORCID 0000-0001-6965-3745 Nuria MonteroNephrology Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.
Anna ManonellesNephrology Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.
Ana ColomaNephrology Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.ORCID 0000-0002-1773-9560 Alexandre FavàNephrology Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.
Josep M GrinyóMedicine Unit, Department of Clinical Sciences, University of Barcelona, 08028 Barcelona, Spain.
Josep M CruzadoNephrology Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.ORCID 0000-0003-1388-8558 Helena ColomBiopharmaceutics and Pharmacokinetics Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, School of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.
Nuria LloberasNephrology Department, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.
Funding
Bellvitge University Hospital The renal diseases funding VAR22002by Instituto de Salud Carlos III and Ministerio de Sanidad y Consumo PI18/01740, PI21/00559RICORS kidney disease, RD21/00050021
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
conversion ratioCYP3A5immunosuppressionIR-TacLCP-Tacpopulation pharmacokineticstacrolimus
Identifiers
PMID41012521
PMCPMC12473248
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390